Grand Pharma shares rise nearly 5% after CBT-001 Phase 3 success
AI Summary- Grand Pharma’s CBT-001 met primary endpoints in an international Phase 3 trial.
- Grand Pharma shares rose nearly 5% intraday on the 5th.
- The stock traded at HK$4.465 as of press time.